Organization
Abbott Laboratories
14 abstracts
Abstract
"ROUTINE APGAR-LIKE PATIENT INDEX DATASHEET"(RAPID): A CONTINUOUS INDEX OF PATIENT MEASURES DISCRIMINATES EFFECTIVELY BETWEEN ACTIVE AND PLACEBO TREATMENTS IN 4 ADALIMUMAB CLINICAL TRIALSOrg: Medicine and Frontier Science Center of Disease Molecular Network, Vanderbilt University Medical Center, Nashville, Biostatistics, Indiana University School of Medicine, Indianapolis, IN, Quintiles, Inc.,
Abstract
ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE PROVIDES SUSTAINED IMPROVEMENTS IN PHYSICAL FUNCTION OVER 2 YEARS OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITISOrg: Abbott Laboratories, Immunoscience Development Center, Abbott Laboratories,
Abstract
5-YEAR CLINICAL AND RADIOGRAPHIC EFFICACY WITH ADALIMUMAB OR ADALIMUMAB PLUS METHOTREXATE AFTER 2 YEARS OF COMBINATION THERAPY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (RA) Org: Abbott Laboratories, Maastricht University Medical Center, Karolinska University Hospital, Karolinska Institutet,
Abstract
A MARKOV MODEL OF LONG-TERM COST EFFECTIVENESS OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS IN CANADA Org: Abbott Laboratories, Medical University of South Carolina Hollings Cancer Center,
Abstract
ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB BIND TO SOLUBLE AND TRANSMEMBRANE TNF WITH SIMILAR AFFINITIESOrg: Abbott Bioresearch Center, Abbott Laboratories,
Abstract
A RANDOMIZED, CONTROLLED, SAFETY TRIAL OF ADALIMUMAB (D2E7), A FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY, GIVEN TO RA PATIENTS IN COMBINATION WITH STANDARD RHEUMATOLOGIC CARE: THE STAR (SAFETY TRIAL OF ADALIMUMAB IN RHEUMATOID ARTHRITIS) TRIALOrg: Denver Arthritis Clinic, University of California Irvine, Stanford University School of Medicine, St. Paul Medical Center, University of Massachusetts Chan Medical School,
Abstract
ADALIMUMAB REDUCES INFLAMMATION IN THE SACROILIAC JOINTS OF PATIENTS WITH ACTIVE SPONDYLOARTHRITIS WITHOUT RADIOGRAPHIC SACROILIITIS — RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL THROUGH 52 WEEKS Org: Abbott Laboratories, Abbott GmbH & Co KG, Wiesbaden, Germany, German Rheumatism Research Centre, Pathophysiology of Rheumatic Inflammation, Berlin, Germany, Centre of Rheumatology, Herne,
Abstract
ADALIMUMAB REDUCES HAND BONE LOSS IN RHEUMATOID ARTHRITIS (RA) INDEPENDENT OF CLINICAL RESPONSE: SUBANALYSIS OF THE PREMIER STUDY Org: Abbott Laboratories, Sectra, UCSD, San Diego, CA,
Abstract
ADALIMUMAB (HUMIRA®) DOSING FREQUENCY IN RA PATIENT ASSISTANCE PROGRAMSOrg: Public Health Policy and Strategy, Abbott Laboratories, Abbott Park, Abbott Laboratories, Abbott Park, Abbott Park, IL, United States,
Abstract
ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE IS SAFE AND EFFICACIOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS INTO THE 7TH YEAR OF THERAPYOrg: Abbott GmbH and Co. KG, Abbott Laboratories,
Abstract
ADALIMUMAB TREATMENT EFFECTS ON QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM ADEPTOrg: Abbott Laboratories, Houston Institute for Clinical Research, Swedish Medical Center, Department of Medicine, University of Toronto, Department of Rheumatology, Leeds General Infirmary,
Abstract
ADALIMUMAB PLUS METHOTREXATE VS. METHOTREXATE MONOTHERAPY FOR EARLY RHEUMATOID ARTHRITIS: 26-WEEK RESULTS (FIRST PHASE) FROM THE 78-WEEK OPTIMA STUDY Org: Abbott Laboratories, Abbott GmbH & Co., KG, Division of Rheumatology, Allergy, and Immunology, University of California San Diego,
Abstract
ADALIMUMAB REDUCES SPINAL AND SACROILIAC JOINT INFLAMMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS)—52 WEEK MAGNETIC RESONANCE IMAGING (MRI) RESULTS FROM THE CANADIAN AS STUDYOrg: Abbott Laboratories, Center for Inflammatory and Arthritis Disease Studies, Groupe de Recherche des Maladies Rhumatismales du Quebec,
Abstract
ADALIMUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS WITH OLIGOARTICULAR ARTHRITIS: SUBANALYSIS OF ADEPTOrg: Abbott Laboratories, Clinical and Academic Rheumatology, Arthritis and Rheumatic Diseases, Oregon Health Sciences University, Portland,